Flores, Nemesia R.

HRN: 11-01-76  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/12/2026
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
04/12/2026
04/19/2026
IV
2.25G
Q8
CRBSI
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Bloodstream    Compliance to guidelines: